Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gapWHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agenciesNovartis making treatment available on largely not-for-profit basis in areas where malaria is endemicBasel, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms. The decision is a key step towards enabling widespread access through public sector procurement. Coartem Baby is also known as Riamet® Baby in some countries and was developed in collaboration with Medicines...

Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gapWHO prequalification key milestone for donor-funded and public sector purchasing by UN and other procurement agenciesNovartis making treatment available on largely not-for-profit basis in areas where malaria is endemicEast Hanover, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms. The decision is a key step towards enabling widespread access through public sector procurement. Coartem Baby is also known as Riamet® Baby in some countries and was developed in collaboration with Medicines...

The Board of Telia Lietuva, AB (hereinafter “Telia Lietuva” or “the Company”) approved unaudited Telia Lietuva, AB Interim Financial Statements, prepared according to International Financial Reporting Standards as adopted by the European Union, for 3 months’ period ended 31 March 2026. First quarter of 2026 (compared with the same period a year ago):Revenue grew by 7.6% and amounted to EUR 128.8 million (EUR 119.8 million) Adjusted EBITDA up by 8.2% to EUR 52.2 million (EUR 48.3 million EBITDA increased by 7.0% and amounted to EUR 51.2 million (EUR 47.8 million) Profit for the period went up by 9.0% to EUR 24.6 million (EUR 22.6 million) Capital investments increased by 19.2% and amounted to EUR 11.3 million (EUR 9.5 million) Free cash flow went up by 28.6% and amounted to EUR 40.2 million (EUR 31.3 million)Comment by Giedrė Kaminskaitė-Salters,...

  Press Release April 24, 2026 Signify reports first quarter 2026 results with resilient margins and cash flow amid continued market softness Highlights 1Signify’s installed base of connected light points increased to 171 million in Q1 26 Sales of EUR 1,274 million with a CSG of -5.1% (Q1 25: -2.8%) Adj. EBITA margin of 6.5% (Q1 25: 8.0%) Net income of EUR 8 million including restructuring costs of EUR 63 million mainly related to the recently announced cost reduction program (Q1 25: EUR 67 million) Free cash flow of EUR 47 million (Q1 25: EUR 40 million) Signify launched its new Brighter Lives, Better World 2030 program, designed to expand the reach of impactful, energy and resource-efficient lighting to improve lives, save energy, and preserve resourcesEindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader...

IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, starts today its Proteus User Meeting 2026 in Belgium. Oncologists, physicists, clinicians from the most prestigious worldwide cancer care institutions across the Americas, Europe and Asia-Pacific will gather this week for the largest meeting of proton therapy experts. These three days of scientific exchange focuses on improving outcomes for cancer patients worldwide. This 2026 edition also marks a symbolic milestone: 25 years since the very first patient was treated with a Proteus® system. That...

(2026-04-24) Kitron today reported record quarterly revenue, operating profit and order backlog, driven by accelerating demand in the Defence/Aerospace market sector. Kitron’s revenue for the first quarter was EUR 272.7 million, an increase of 66 per cent from 164.6 million in the same quarter last year. The Defence/Aerospace market sector continued to lead, but all market sectors grew compared to a year ago. First-quarter operating profit (EBIT) was EUR 25.6 million, compared with 12.5 million in the same quarter last year. Profitability expressed as EBIT margin was 9.4 per cent, compared with 7.6 per cent in the same quarter last year. This is in line with the strategic target of maintaining an EBIT margin above 9 per cent. The order backlog ended at an all-time high of EUR 805.9 million, an increase of 54 per cent compared with...

Stronger seasonality impact in Q1 not affecting full-year outlookOutstanding bolt-on M&A activity in GermanySustained momentum in underlying trendsCergy, April 24th, 2026Stronger seasonality impact in Q1 2026Q1 2026 revenue: €2,450.3 million, up +1.7% year-on-year at constant FX Organic growth of -0.9%, reflecting temporary weather-related disruptions in Germany and Central Europe; gradual catch-up expected over the coming quarters +2.7% contribution from 2025 bolt-on acquisitions Structural growth trends unaltered, supported by sustained momentum in Europe to strengthen energy sovereignty and advance the energy transitionOutstanding M&A activity in Germany and Central EuropeExceptional start to the year, with four transactions announced early 2026, representing approximately €667 million of annual revenueMajor scale-up...

PRESSRELEASE NANTERRE, FRANCE Friday, April 24, 2026    1st QUARTER INFORMATION SOLID Q1 SALES IGNITE PRIORITIES IN MOTIONQ1 Sales of €5.1bn with organic growth across all regions except China 2026 guidance confirmedQ1 organic sales: outperformance of 120 bps vs. market volume down 3.4%Organic growth and outperformance in Europe, North America and Rest of Asia; unfavorable customer mix in China Electronics supporting Growth cluster performance; moderate organic growth in the Value clusterGood commercial momentum in high-growth regions and segmentAccelerated development in India and customer diversification in China Market share gains in Interior Monitoring Systems technologiesReinforced cost and cash discipline supporting performanceContinued rigorous execution of EU-FORWARD and SIMPLIFY programs Objective to fully mitigate...

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS CALGARY, Alberta, April 24, 2026 (GLOBE NEWSWIRE) — Questerre Energy Corporation (“Questerre” or the “Company”) reported today it has entered into a binding agreement to sell its non-operated minority working interest in its Kakwa Central assets for total consideration of $23.5 million. Pursuant to a purchase and sale agreement, the consideration includes a cash payment of $23.5 million, the assumption of decommissioning liabilities for the assets as well as the Company’s commitments under its firm transportation and processing contracts. The agreement is scheduled to close on May 1, 2026, and is subject to receipt of requisite approvals and customary adjustments. Production...